Does Severity of Alzheimer's Disease Contribute to Its Responsiveness to Modifying Gut Microbiota? A Double Blind Clinical Trial

被引:156
|
作者
Agahi, Azadeh [1 ]
Hamidi, Gholam Ali [1 ]
Daneshvar, Reza [2 ]
Hamdieh, Mostafa [3 ]
Soheili, Masoud [1 ]
Alinaghipour, Azam [1 ]
Taba, Seyyed Mohammad Esmaeili [4 ]
Salami, Mahmoud [1 ]
机构
[1] Kashan Univ Med Sci, Physiol Res Ctr, Kashan, Iran
[2] Kashan Univ Med Sci, Dept Neurol, Sch Med, Kashan, Iran
[3] Shaheed Beheshti Univ Med Sci, Sch Med, Dept Psychol, Tehran, Iran
[4] Farhangian Univ, Dept Educ, Taleghani Branch, Qom, Iran
来源
FRONTIERS IN NEUROLOGY | 2018年 / 9卷
关键词
probiotics; Alzheimer's disease; cognition; inflammation; oxidative stress; microbiota; MILD COGNITIVE IMPAIRMENT; OXIDATIVE STRESS; PROBIOTIC SUPPLEMENTATION; MULTIPLE-SCLEROSIS; EXPRESSION; INTERLEUKIN-6; INFLAMMATION; PROTEIN; HEALTH; MEMORY;
D O I
10.3389/fneur.2018.00662
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Alzheimer's disease (AD) is associated with cognitive dysfunction. Evidence indicates that gut microbiota is altered in the AD and, hence, modifying the gut flora may affect the disease. In the previous clinical research we evaluated the effect of a probiotic combination on the cognitive abilities of AD patients. Since, in addition to pathological disorders, the AD is associated with changes in oxidant/antioxidant and inflammatory/anti-inflammatory biomarkers, the present work was designed to evaluate responsiveness of the inflammatory and oxidative biomarkers to the probiotic treatment. The control (CON) and probiotic (PRO) AD patients were treated for 12 weeks by the placebo and probiotic supplementation, respectively. The patients were cognitively assessed by Test Your Memory (TYM = 50 scores). Also serum concentrations of nitric oxide (NO), glutathione (GSH), total antioxidant capacity (TAC), malondialdehyde (MDA), 8-hydroxy-2'-deoxyguanosine (8-OHdG) and cytokines (TNF-a, IL-6, and IL-10) were measured. The cognitive test and the serum biomarkers were assessed pre- and post-treatment. According to TYM test 83.5% of the patients showed severe AD. The CON (12.86% +/- 8.33) and PRO (-9.35% +/- 16.83) groups not differently scored the cognitive test. Not pronounced change percent was found in the serum level of TNF-alpha (1.67% +/- 1.33 vs. -0.15% +/- 0.27), IL-6 (0.35% +/- 0.17 vs. 2.18% +/- 0.15), IL-10 (0.05% +/- 0.10 vs. -0.70% +/- 0.73), TAC (0.07% +/- 0.07 and -0.06% +/- 0.03), GSH (0.08% +/- 0.05 and 0.04% +/- 0.03) NO (0.11% +/- 0.06 and 0.05% +/- 0.09), MDA (-0.11% +/- 0.03 and -0.17% +/- 0.03), 8-OHdG (43.25% +/- 3.01 and 42.70% +/- 3.27) in the CON and PRO groups, respectively. We concluded that the cognitive and biochemical indications in the patients with severe AD are insensitive to the probiotic supplementation. Therefore, in addition to formulation and dosage of probiotic bacteria, severity of disease and time of administration deeply affects results of treatment.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Commentary: Does Severity of Alzheimer's Disease Contribute to Its Responsiveness to Modifying Gut Microbiota? A Double Blind Clinical Trial
    Leblhuber, Friedrich
    Steiner, Kostja
    Schuetz, Burkhard
    Fuchs, Dietmar
    FRONTIERS IN NEUROLOGY, 2019, 10
  • [2] Does Severity of Alzheimer's Disease Contribute to Its Responsiveness to Modifying Gut Microbiota? A Double Blind Clinical Trial (vol 9, 662, 2018)
    Agahi, Azadeh
    Hamidi, Gholam Ali
    Daneshvar, Reza
    Hamdieh, Mostafa
    Soheili, Masoud
    Alinaghipour, Azam
    Taba, Seyyed Mohammad Esmaeili
    Salami, Mahmoud
    FRONTIERS IN NEUROLOGY, 2019, 10
  • [3] Gut Microbiota and Alzheimer's Disease: Experimental Evidence and Clinical Reality
    Saha, Sarama
    Singh, Sukhpal
    Prasad, Suvarna
    Mittal, Amit
    Sharma, Anil K.
    Chakrabarti, Sasanka
    CURRENT ALZHEIMER RESEARCH, 2021, 18 (10) : 787 - 801
  • [4] Microglia and gut microbiota: A double-edged sword in Alzheimer's disease
    Bano, Nargis
    Khan, Sameera
    Ahamad, Shakir
    Kanshana, Jitendra Singh
    Dar, Nawab John
    Khan, Sumbul
    Nazir, Aamir
    Bhat, Shahnawaz Ali
    AGEING RESEARCH REVIEWS, 2024, 101
  • [5] Gut microbiota and its metabolites in Alzheimer's disease: from pathogenesis to treatment
    Zou, Xinfu
    Zou, Guoqiang
    Zou, Xinyan
    Wang, Kangfeng
    Chen, Zetao
    PEERJ, 2024, 12 : 2 - 32
  • [6] Gut Microbiota and its Metabolites: Bridge of Dietary Nutrients and Alzheimer's Disease
    Zhu, Guangsu
    Zhao, Jianxin
    Zhang, Hao
    Wang, Gang
    Chen, Wei
    ADVANCES IN NUTRITION, 2023, 14 (04) : 819 - 839
  • [7] Disease-modifying therapies for Alzheimer's disease: Clinical trial progress and opportunity
    Zhang, Yujie
    Chen, Jie
    Li, Yanru
    Jiao, Bin
    Luo, Shilin
    AGEING RESEARCH REVIEWS, 2025, 103
  • [8] SARS-CoV-2-Indigenous Microbiota Nexus: Does Gut Microbiota Contribute to Inflammation and Disease Severity in COVID-19?
    Chattopadhyay, Indranil
    Shankar, Esaki M.
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2021, 11
  • [9] "Gut microbiota modulation in Alzheimer's disease: Focus on lipid metabolism" Clinical Nutrition 2022
    Fidelis, Debora Eduarda da Silva
    Ramos, Tiago Lacerda
    Filguera, Tayrine Ordonio
    Santos, Gabriela Carvalho Jurema
    Fernandes, Matheus Santos de Sousa
    CLINICAL NUTRITION, 2024, 43 (11) : 153 - 153
  • [10] Alzheimer's disease and gut microbiota: does trimethylamine N-oxide (TMAO) play a role?
    Cardoza, Pablo Arrona
    Spillane, Micheil B.
    Marroquin, Elisa Morales
    NUTRITION REVIEWS, 2022, 80 (02) : 271 - 281